Valuence Merger Corp. I
Searching since IPO 2022-03-02- CIK 1892747
- VMCA
- IPO 2022-03-02
- $5.9M trust
- 147 filings
- IPO Size
- $220M
- raised at the IPO
- Trust
- $5.9M
- as of 2026-06-30
- Current Status
- Unit Split
- from its latest filing
- IPO Year
- 2022
- year it listed
Filings, by quarter
147 filings over 21 quarters; violet bars carry a milestone
- 21 Q4: 2 filings
- 22 Q1: 30 filings
- 22 Q2: 3 filings
- 22 Q3: 1 filing
- 22 Q4: 1 filing
- 23 Q1: 7 filings
- 23 Q2: 10 filings
- 23 Q3: 8 filings
- 23 Q4: 4 filings
- 24 Q1: 15 filings
- 24 Q2: 16 filings
- 24 Q3: 4 filings
- 24 Q4: 9 filings
- 25 Q1: 7 filings
- 25 Q2: 5 filings
- 25 Q3: 5 filings
- 25 Q4: 4 filings
- 26 Q1: 6 filings
- 26 Q2: 4 filings
- 26 Q3: 5 filings
- 26 Q4: 1 filing
- S-1 filed 21 Q4
- IPO 22 Q1
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Valuence Merger Corp. I is a blank-check company formed to identify and combine with an operating business. Its stated objective is to pursue a growth-oriented Asian business, emphasizing breakthrough life-sciences and sustainability technology.
Investment Focus
Biopharmaceuticals, Healthcare, Agriculture, Consumer, Energy, Materials, Natural Resources, Transportation
Geographic Focus
Asia (excluding China, Hong Kong and Macau)
Key Information
As the filings state it
- IPO Date
- 2022-03-02
- Total Redemptions
- $235M
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- SPAC Ticker
- VMCA
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team brings experience in private equity, investment banking, venture capital, M&A, sustainable technology and infrastructure, biopharmaceuticals and healthcare. Its executives and directors include the founders of Credian Partners and CrystalGenomics, with prior SPAC experience and support from Quantum Leaps.